Wood M J, Shukla S, Fiddian A P, Crooks R J
Department of Infection, Heartlands Hospital, Birmingham, United Kingdom.
J Infect Dis. 1998 Nov;178 Suppl 1:S81-4. doi: 10.1086/514271.
The efficacy of early versus late treatment with acyclovir and valaciclovir on zoster-associated pain was assessed from two databases (1076 patients) that were compiled from randomized trials. Early treatment was started < 48 h and late treatment was started 48-72 h after the onset of cutaneous herpes zoster. Median times to complete resolution of zoster-associated pain were 28 and 62 days, respectively, for patients (> or = 18 years of age) treated with acyclovir and placebo within 48 h (hazard ratio [HR], 1.68; 95% confidence limit [95% CL], 1.19, 2.38) and 28 and 58 days, respectively, for those treated later (HR, 2.20; 95% CL, 1.03, 4.71). In the valaciclovir versus acyclovir study (in patients > or = 50 years of age), the corresponding figures were 44 and 51 days for patients treated early (HR, 1.28; 95% CL, 1.03, 1.60) and 36 and 48 days for those treated later (HR, 1.40; 95% CL, 1.04, 1.87). Acyclovir significantly shortened the time to complete resolution of zoster-associated pain compared with placebo (and valaciclovir was superior to acyclovir in this regard) even when therapy was delayed up to 72 h after rash onset.
从两个由随机试验汇编而成的数据库(共1076例患者)中评估了阿昔洛韦和伐昔洛韦早期与晚期治疗对带状疱疹相关性疼痛的疗效。早期治疗在皮肤性带状疱疹发作后<48小时开始,晚期治疗在发作后48 - 72小时开始。对于在48小时内接受阿昔洛韦和安慰剂治疗的(≥18岁)患者,带状疱疹相关性疼痛完全缓解的中位时间分别为28天和62天(风险比[HR],1.68;95%置信区间[95%CL],1.19,2.38),而对于较晚接受治疗的患者,分别为28天和58天(HR,2.20;95%CL,1.03,4.71)。在伐昔洛韦与阿昔洛韦的研究中(≥50岁的患者),早期治疗患者的相应数字为44天和51天(HR,1.28;95%CL,1.03,1.60),较晚治疗患者为36天和48天(HR,1.40;95%CL,1.04,1.87)。与安慰剂相比,阿昔洛韦显著缩短了带状疱疹相关性疼痛完全缓解的时间(在这方面伐昔洛韦优于阿昔洛韦),即使在皮疹发作后延迟治疗长达72小时。